If You Invested $1,000 in Septerna, Inc. (SEPN)
This article analyzes the hypothetical return on a $1,000 investment in Septerna, Inc. (SEPN), a clinical-stage biotechnology company specializing in GPCR-targeted therapies. An investment made one year ago would have yielded a 213.4% return, turning $1,000 into $3,134. The company utilizes its proprietary Native Complex Platform™ to develop oral small molecule drug candidates across various therapeutic areas, including endocrinology, immunology, inflammation, and metabolic diseases, and has collaborations with companies like Novo Nordisk.
Septerna (SEPN) SVP Long exercises options and sells 3,333 shares in Rule 10b5-1 trades
Daniel D. Long, Senior Vice President of Drug Discovery at Septerna, Inc. (SEPN), exercised stock options to acquire 3,333 shares at $2.76 each and simultaneously sold these 3,333 shares in open-market transactions on July 1, 2026. The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 20, 2026, with weighted average prices ranging from $34.0964 to $34.8141. These transactions are considered a routine liquidity move, converting incentive compensation into cash, and are not seen as indicative of a significant change in the insider's view of the company.
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN) and Strategy (MSTR)
Guggenheim analyst Seamus Fernandez reiterated a Buy rating on Septerna, Inc. (SEPN) with a $45.00 price target, reflecting a current consensus Strong Buy with a 38.9% upside. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating on Strategy (MSTR) with a $130.00 price target. The overall analyst consensus for Strategy is a Strong Buy with a significant 250.6% upside from an average target of $302.25.
Septerna (SEPN) Is Down 7.1% After Broad Russell Index Additions Has The Bull Case Changed?
Septerna, Inc. (NasdaqGM: SEPN) was recently added to several Russell growth and small-cap indexes in late June 2026, which could increase its visibility among institutional investors. Despite a recent 7-day share price decline, this index inclusion primarily impacts trading liquidity and visibility rather than the core scientific drivers of the early-stage biotech company. The investment narrative for Septerna continues to rely on its pipeline, the Novo Nordisk partnership, and upcoming clinical data, with funding and potential dilution remaining key risks.
Truist Securities Adjusts Septerna Price Target to $43 From $35, Maintains Buy Rating
Truist Securities has increased its price target for Septerna, Inc. (NasdaqGM:SEPN) to $43 from $35, while reiterating a "Buy" rating on the stock. This adjustment reflects an updated positive outlook from the firm regarding the biotechnology company. Septerna is a clinical-stage biotechnology company focused on developing oral small-molecule drugs for various therapeutic areas using its proprietary Native Complex Platform.
SEPN Maintains Buy Rating - Price Target Raised to $43.00 by Truist Securities
Truist Securities analyst Srikripa Devarakonda has maintained a "Buy" rating for Septerna (SEPN) and increased its price target from $35.00 to $43.00, suggesting optimism about the company's future performance. Despite this positive outlook, Septerna has a low GF Score™ of 12/100, primarily due to weak profitability, though it shows strong financial strength. Investors should consider both the analyst's confidence and the company's financial metrics.
Septerna stock maintained at Buy by H.C. Wainwright after rival setback
H.C. Wainwright has reiterated a Buy rating and a $40 price target for Septerna Inc (NASDAQ:SEPN) despite a competitor's negative Phase 2b data in chronic spontaneous urticaria. The firm maintains that Septerna's drug SEP-631, which targets the same condition, still has potential avenues for success, even if the path has narrowed due to competitor failures. Septerna also shows strong financial health with more cash than debt, supporting its pipeline development.
Guggenheim cuts Septerna stock price target to $45 on CSU study risk
Guggenheim lowered its price target for Septerna Inc. (NASDAQ:SEPN) to $45 from $52, while maintaining a Buy rating. This adjustment follows a competitor's failed Phase 2b study for chronic spontaneous urticaria (CSU), increasing the perceived risk for Septerna's similar drug candidate, SEP-631. Despite this, Guggenheim increased its market share estimate for Septerna’s hypoparathyroidism drug, SEP-479, due to positive feedback.
Septerna (SEPN) director Abraham Bassan receives grant of 15,000 stock options
Septerna, Inc. director Abraham Bassan was granted 15,000 stock options with an exercise price of $37.34 per share, expiring on June 25, 2036. These options will vest in full on the earlier of June 26, 2027, or the date of Septerna's next annual meeting of stockholders, provided he continues his service to the company. This grant is part of his compensation and is not an open-market transaction.
Septerna (SEPN) director Jeffrey Tong granted options on 15,000 shares
Septerna, Inc. director Jeffrey K. Tong was granted stock options for 15,000 shares of common stock. The options have an exercise price of $37.34 per share and expire on June 25, 2036. These options will vest in full on the earlier of June 26, 2027, or the date of Septerna’s next annual stockholder meeting, provided Tong continues his service to the company.
Septerna chief people officer Samira Shaikhly sells $76,622 in stock
Samira Shaikhly, Septerna's Chief People Officer, sold 2,178 shares of the company's common stock for $76,622 after exercising stock options. The sale was conducted under a Rule 10b5-1 trading plan. This transaction follows a significant 216% surge in Septerna's share price over the past year, and the company is advancing its clinical pipeline with positive trial results and increased price targets from analysts.
Septerna (SEPN) director Bernard Coulie receives 15,000 stock options
Septerna, Inc. (SEPN) director Bernard Coulie was granted 15,000 stock options with an exercise price of $37.34 per share, expiring on June 25, 2036. The options will vest in full by the earlier of June 26, 2027, or the company's next annual stockholders' meeting, provided he continues his service. This transaction is a compensation-related award rather than an open-market purchase or sale.
Form 4 Septerna Inc For: 30 June By Investing.com
This article provides a Form 4 filing for Septerna Inc. for the period ending June 30. It is a brief corporate financial regulatory update published by Investing.com. The content focuses on the public filing, with minimal additional detail beyond its existence and date.
Septerna (NASDAQ: SEPN) director-linked funds get 15,000-share option
Septerna, Inc. (NASDAQ: SEPN) has granted a stock option for 15,000 shares of common stock at an exercise price of $37.34, expiring on June 25, 2036. This option, which vests upon the earlier of June 26, 2027, or the next annual stockholder meeting, is held by Dr. Simson for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund III LP. The net proceeds from the exercise will offset advisory fees owed to RA Capital's adviser entities.
Septerna (SEPN) director Shalini Sharp receives stock options on 15,000 shares
Septerna, Inc. director Shalini Sharp was granted stock options for 15,000 shares of common stock. The options have an exercise price of $37.34 per share and will expire on June 25, 2036. These options will vest in full on the earlier of June 26, 2027, or the company's next annual meeting of stockholders, contingent on her continued service.
Cantor Fitzgerald Maintains Septerna(SEPN.US) With Buy Rating, Raises Target Price to $60
Cantor Fitzgerald has reiterated its Buy rating for Septerna (SEPN.US) and increased the price target to $60. This adjustment reflects the firm's continued positive outlook on the company's stock performance.
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
An insider at Septerna, Daniel D. Long, SVP of Drug Discovery, sold 15,000 shares of common stock after exercising options, reducing his direct holdings by 13.46%. Despite this sale, the article suggests it's likely a form of income supplementation rather than a lack of confidence, as he still retains significant direct shares and unexercised options. Septerna, a clinical-stage biotech company partnered with Novo Nordisk, is developing oral small molecule therapeutics, with promising Phase 1 trial results for SEP-631.
ETFs Investing in Septerna, Inc. Stocks
This article lists various ETFs that hold Septerna, Inc. (SEPN) stocks, providing detailed information such as market value, weight, issuer, management style, focus, and expense ratio for each fund. The data highlights ETFs from major issuers like BlackRock, State Street, and Invesco, with a focus on small-cap and healthcare biotechnology sectors. Investors can use this information to explore different investment opportunities in ETFs that include Septerna, Inc. as a holding.
Septerna, Inc.(NasdaqGM:SEPN) added to Russell 2000 Growth Benchmark
Septerna, Inc. (NasdaqGM: SEPN) has been included in the Russell 2000 Growth Benchmark, a significant development for the clinical-stage biotechnology company. This inclusion indicates increased visibility and potential liquidity for Septerna's stock. The company focuses on developing G protein-coupled receptor (GPCR) oral small-molecule drugs for endocrinology, immunology and inflammation, and metabolic diseases.
Form 144 SEPTERNA For: 26 June By Investing.com
This article from Investing.com is a simple, brief notice about a Form 144 filing for SEPTERNA on June 26th. It provides no further details beyond the filing date and company name. The rest of the content includes market data, news headlines, and navigational elements typical of a financial news website.
SEPN (NASDAQ) insider sale: JAE KIM sells 94,339 shares under Rule 144
JAE KIM, an insider at Septerna, Inc. (NASDAQ: SEPN), sold 94,339 shares of common stock on June 22, 2026, for proceeds of $3,326,119.56, as reported in a Rule 144 filing on June 26, 2026. This notice details proposed transactions of restricted shares and also lists prior Employee Stock Purchase Plan entries. While showing a completed sale, Rule 144 filings are administrative and further SEC filings will confirm settlement and ownership impact.
Septerna, Inc. Actuals & Estimates (NASDAQ:SEPN)
This article provides an in-depth financial overview of Septerna, Inc. (NASDAQ: SEPN), including its current stock price, historical performance, analyst forecasts, and detailed financial statements. It covers actual and estimated earnings, revenue, net income, market capitalization, and upcoming earnings dates, offering a comprehensive look for investors.
Form 4 Septerna Inc For: 24 June By Investing.com
This article reports on a Form 4 filing for Septerna Inc. on June 24, as published by Investing.com. It is a brief news item indicating an insider trading report for the company.
SEPN Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Septerna, Inc. (SEPN) stock, based on analyst opinions. It highlights the company's recent stock performance, financial data including earnings and revenue, and key metrics such as market capitalization and volatility. The consensus analyst forecast indicates a potential price range for SEPN, alongside a recommendation to buy based on its technical analysis.
Form 4 Septerna Inc For: 24 June By Investing.com
This article announces the filing of Form 4 for Septerna Inc. on June 24, as reported by Investing.com. The content primarily lists market data, popular news headlines, and various financial tools available on the Investing.com platform, with minimal specific detail about Septerna Inc.'s filing.
Septerna (SEPN) SVP sells 15,000 shares under 10b5-1 plan
Daniel D. Long, SVP of Drug Discovery at Septerna, Inc. (SEPN), reported exercising options for 15,000 shares and then selling all 15,000 of those shares on June 22, 2026, under a pre-arranged Rule 10b5-1 plan. The sales were made at weighted average prices of $35.9687 and $35.1001, totaling approximately $533,000. Following these transactions, Long directly holds 96,412 shares of Septerna common stock.
Form 4 Septerna Inc For: 24 June By Investing.com
This article announces the filing of a Form 4 for Septerna Inc. on June 24, as reported by Investing.com. The Form 4 is a document used to report changes in beneficial ownership of a company's stock by insiders. The article provides a stock ticker (SEPN) and its performance (-1.94%).
Septerna SVP, drug discovery, sells $532,581 in stock
Septerna's Senior Vice President of Drug Discovery, Daniel D. Long, sold $532,581 worth of company common stock after exercising options. These transactions occurred under a Rule 10b5-1 sales plan as Septerna's stock trades near its 52-week high after a significant gain. The company is actively advancing its drug candidates, with recent positive developments in its clinical trials for SEP-479 and SEP-631, leading to reaffirmed "Buy" ratings and increased price targets from analysts.
Septerna SVP, drug discovery, sells $532,581 in stock
Septerna's Senior Vice President of Drug Discovery, Daniel D. Long, sold $532,581 worth of company common stock on June 22, 2026, after exercising stock options. This sale was part of a Rule 10b5-1 plan, with the stock trading near its 52-week high after a 237% gain. The company's stock is considered overvalued by InvestingPro analysis, despite recent positive developments in its clinical trials and reiterated "Buy" ratings from analysts.
Septerna stock hits all-time high at 37.32 USD
Septerna Inc.'s stock reached an all-time high of $37.32, marking a 248.09% increase over the past year. Despite an InvestingPro analysis suggesting potential overvaluation, investor confidence remains strong. The company is advancing its clinical pipeline, with recent developments including initiating a Phase 1 trial for SEP-479 and positive Phase 1 results for SEP-631, leading analysts to maintain strong ratings and raise price targets.
Septerna stock hits all-time high at 37.32 USD By Investing.com
Septerna Inc.'s stock reached an all-time high of $37.32, currently trading at $37.39 with a market capitalization of $1.68 billion, reflecting robust market performance. The company has initiated a Phase 1 clinical trial for SEP-479 for hypoparathyroidism and plans a Phase 2b trial for SEP-631 in chronic spontaneous urticaria. Analysts like Raymond James and H.C. Wainwright maintain "Strong Buy" and "Buy" ratings respectively, with price targets of $53 and $40, based on promising trial results and pipeline assets.
Number of shareholders of Septerna, Inc. – NASDAQ:SEPN
This article provides details on the number of shareholders for Septerna, Inc. (NASDAQ:SEPN). It presents financial information and standard company data points for the biotech company listed on the Nasdaq Stock Market.
[144] Septerna, Inc. SEC Filing
This article details a Form 144 SEC filing by Septerna, Inc. (SEPN). The filing indicates a proposed sale of 25,000 common shares with an aggregate market value of $904,250.00, acquired through the exercise of stock options. The securities are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.
Septerna (NasdaqGM:SEPN) Stock Forecast & Analyst Predictions
Septerna (NasdaqGM:SEPN) is projected to experience declines in revenue and earnings, with EPS expected to fall by 28% annually. Despite this, the company has several upcoming clinical catalysts for its GPCR-focused pipeline and recently saw increased consensus revenue estimates for 2026. However, insider selling has been noted, and the company remains unprofitable with a demanding valuation.
Wells Fargo Keeps Their Buy Rating on Septerna, Inc. (SEPN)
Wells Fargo analyst Derek Archila has maintained a Buy rating on Septerna, Inc. (SEPN) and set a price target of $48.00. This follows Guggenheim also initiating coverage with a Buy rating and a $52.00 price target. Septerna recently reported quarterly revenue of $26.52 million and a GAAP net loss of $8.64 million, showing significant growth from the previous year's revenue of $219 thousand.
Septerna Inc (SEPN) Institutional Confidence
Septerna Inc (SEPN) has an institutional shareholding score of 10.00, placing it first among 388 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 5.10% quarter-over-quarter to 106.37%. John Hussman is the largest institutional shareholder, holding 84.59K shares, which represents 0.23% of outstanding shares.
Septerna Inc (SEPN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Septerna Inc (SEPN), detailing its current earnings forecast score, analyst ratings, and price targets. It highlights that the company ranks 122 out of 388 in its industry, with analysts largely recommending a "Buy" for its stock. The report also includes FAQs on expected revenue, price targets, and past EPS performance.
Septerna’s chief people officer sells $219k in shares
Septerna's Chief People Officer, Samira Shaikhly, sold 6,250 shares of the company's common stock for over $219,000 after exercising stock options. The sale was executed via a Rule 10b5-1 sales plan, with the stock trading near its 52-week high after a significant gain over the past year. This news follows other recent positive developments for Septerna, including progress in clinical trials and favorable analyst ratings.
Septerna’s chief people officer sells $219k in shares
Samira Shaikhly, Chief People Officer at Septerna Inc. (NASDAQ:SEPN), sold 6,250 shares for $219,224 on June 12, 2026, executed under a Rule 10b5-1 sales plan. This transaction followed her acquisition of the same number of shares through stock option exercises at a lower price. The sale aligns with strong recent performance for Septerna's stock and positive analyst coverage concerning its clinical trials for new drug candidates.
Septerna (SEPN) Chief People Officer sells 6,250 shares after option exercise
Septerna, Inc.'s Chief People Officer, Samira Shaikhly, executed an exercise-and-sale transaction, acquiring 6,250 shares at $11.70 each and immediately selling them at a weighted average price of $35.0759 under a pre-arranged Rule 10b5-1 sales plan. Following the transaction, she directly holds 793 shares and retains 23,750 outstanding stock options. The sale generated $219,224, reflecting an insider trading activity outlined in a recent Form 4 filing.
Did SEP-479’s Endocrine Society Spotlight Just Shift Septerna’s (SEPN) Hypoparathyroidism Investment Narrative?
Septerna's experimental drug SEP-479, an oral PTH1R agonist for hypoparathyroidism, received an oral presentation slot at the 2026 Endocrine Society’s Annual Meeting, providing scientific validation and visibility. While this boosts the drug's credibility, the near-term investment narrative for Septerna (SEPN) is still largely tied to its ongoing Phase 1 trial readout expected in late 2026 or early 2027, along with progress on SEP-631 and its collaboration with Novo Nordisk. Investors need to weigh the potential of SEP-479 against Septerna's unprofitability, declining revenue forecasts, and elevated stock price expectations.
SEPN: 8,428 shares proposed sale; Samira Shaikhly 10b5-1 sales listed
A Form 144 notice has been filed for Septerna, Inc. (SEPN) reporting an intended sale of 8,428 shares of Common Stock on June 12, 2026, stemming from the exercise of stock options with a cash payment. The filing also details prior 10b5-1 sales by Samira Shaikhly, specifically 5,935 shares on June 1, 2026, and 11,798 shares on May 26, 2026. This regulatory notice signals proposed future transactions and past automated sales by an insider.
Did SEP-479’s Endocrine Society Spotlight Just Shift Septerna’s (SEPN) Hypoparathyroidism Investment Narrative?
Septerna, Inc. gained scientific validation for its hypoparathyroidism drug, SEP-479, through its acceptance for an oral presentation at the 2026 Endocrine Society’s Annual Meeting, with an ongoing Phase 1 trial. This spotlight enhances SEP-479's potential to offer a once-daily oral therapy, moving beyond current injectable or supplement-based treatments. While this preclinical validation strengthens Septerna's investment narrative, the near-term focus remains on the Phase 1 readout (expected late 2026/early 2027) and progress on SEP-631 and the Novo Nordisk collaboration.
Guggenheim Initiates Septerna at Buy With $52 Price Target
Guggenheim has initiated coverage of Septerna with a "Buy" rating. The firm has set a price target of $52 for Septerna's stock. This initiation suggests a positive outlook from Guggenheim regarding Septerna's future performance.
Septerna Inc stock reaches all-time high at 32.76 USD
Septerna Inc.'s stock has hit an all-time high, reaching $32.76 after a remarkable 209.51% increase over the past year, valuing the biotech firm at $1.45 billion. Despite being slightly overvalued by InvestingPro analysis, analysts maintain bullish price targets due to positive developments including planned clinical trials for hypoparathyroidism and promising Phase 1 trial results for SEP-631.
Guggenheim Initiates Septerna at Buy With $52 Price Target
Guggenheim has initiated coverage on Septerna Inc. (SEPN) with a "Buy" rating and set a price target of $52. This news comes as Septerna continues to advance its pipeline, including presenting at a healthcare conference and reporting recent earnings. The company, a clinical-stage biotechnology firm, focuses on developing oral small-molecule drugs targeting G protein-coupled receptors (GPCRs).
Did SEP-479’s Endocrine Society Spotlight Just Shift Septerna’s (SEPN) Hypoparathyroidism Investment Narrative?
Septerna, Inc. recently highlighted preclinical data for SEP-479, its oral PTH1R agonist for hypoparathyroidism, at the 2026 Endocrine Society’s Annual Meeting, generating scientific validation for the drug currently in Phase 1 trials. While this offers industry visibility, the near-term investment narrative for Septerna will likely be more significantly impacted by the Phase 1 readout expected in late 2026 or early 2027 for SEP-479, and progress on SEP-631 and the Novo Nordisk collaboration. Investors should also consider the company's unprofitability, declining revenue expectations, and potential funding and dilution risks, despite the stock's strong performance over the past year.
Raymond James raises Septerna stock price target on pipeline potential
Raymond James has increased its price target for Septerna Inc. (NASDAQ:SEPN) to $53 from $47, maintaining a Strong Buy rating due to the company's promising pipeline, particularly its SEP-479 and SEP-631 assets. The firm highlights Septerna's strong financial position with more cash than debt and sees significant upside potential from upcoming clinical trial results for both drugs. Other analysts like H.C. Wainwright, Truist Securities, and Cantor Fitzgerald have also reiterated positive ratings and price targets, reflecting confidence in Septerna's clinical progress and financial outlook.
Experimental oral hypoparathyroidism drug SEP-479 gets ENDO 2026 stage
Septerna, Inc. announced that preclinical data for its experimental oral drug, SEP-479, a PTH1R agonist for hypoparathyroidism, will be presented at the 2026 ENDO Annual Meeting. The company highlighted robust in vitro and in vivo activity supporting SEP-479's potential as a once-daily oral treatment. SEP-479 is currently undergoing Phase 1 clinical trials, with data expected in late 2026 or early 2027.
Raymond James raises Septerna stock price target on pipeline potential By Investing.com
Raymond James has increased its price target for Septerna Inc. (NASDAQ:SEPN) to $53 from $47, maintaining a Strong Buy rating, due to the depth and quality of its pipeline assets. The firm highlights the potential of SEP-479, a first-mover oral PTH agonist targeting a multi-billion dollar market, despite the stock being considered slightly overvalued by InvestingPro. Septerna's strong financial position, with more cash than debt and a high current ratio, further supports the positive outlook.
